Nexium (Esomeprazole Magnesium Trihydrate)

Nexium, a proton pump inhibitor, is used to manage acid‑related gastrointestinal disorders.

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining a higher gastric pH.
• Erosive esophagitis: promotes healing of inflamed esophageal tissue by reducing acid exposure.
• Peptic ulcer disease: supports ulcer closure and prevents recurrence through sustained acid suppression.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

• Esomeprazole selectively and irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces basal and stimulated gastric acid secretion, thereby increasing gastric pH and allowing mucosal healing in acid‑related disorders.

Esomeprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually transient.
• Nausea: occasional and mild.
• Abdominal pain: mild discomfort.
• Flatulence: occasional.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): requires immediate medical attention.
• Clostridioides difficile infection: may present with severe diarrhea.
• Low magnesium levels (hypomagnesemia): can lead to muscle cramps or cardiac arrhythmia.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks.

• Renal impairment: assess kidney function and adjust use in severe cases.
• Hepatic disease: use with caution in patients with liver dysfunction.
• Long‑term use: monitor for vitamin B12 deficiency and bone density loss.
• Pregnancy and lactation: evaluate risk‑benefit ratio with a healthcare professional.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Esomeprazole can alter the absorption or metabolism of several concomitant medications.

Major Interactions (Avoid)

• Ketoconazole: reduced antifungal absorption; avoid co‑administration.
• Atazanavir: markedly decreased antiviral exposure; contraindicated.
• Iron salts: decreased iron absorption; separate dosing by at least 2 hours.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR; monitor coagulation parameters.
• Digoxin: possible increase in serum levels; observe for toxicity.
• Methotrexate: reduced clearance may raise toxicity risk; monitor renal function and drug levels.